FDAnews Drug Daily Bulletin

UNITED THERAPEUTICS 'BUY,' TARGET PRICE RAISED

Nov. 2, 2005
A A

nalysts at First Albany reiterate their "buy" rating on United Therapeutics Corp (UTHR.NAS), while raising their estimates for the company. The target price has been raised from $77 to $85. In a research note published this morning, the analysts mention that the company has reported its 3Q:05 EPS significantly ahead of and SG&A expenses lower than the estimates. United Therapeutics' Remodulin sales during the quarter were substantially ahead of the estimates, the analysts say.
Newratings